The MarketWatch News Department was not involved in the creation of this content. Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development ...
Twice a year, influenza experts engage in a critically important forecasting bet: pick three to four vaccine strains now that will match the flu viruses people will face in 8-12 months. The strains ...
Invivyd, Inc. announced new in vitro data demonstrating that its investigational monoclonal antibody PEMGARDA™ (pemivibart) continues to show consistent neutralizing activity against the dominant SARS ...
A research team has successfully developed the world's first nasal organoid-based SARS-CoV-2 neutralizing antibody evaluation platform. Subscribe to our newsletter for the latest sci-tech news updates ...
(A) Cryo-EM structure overview of HSV-1 gB in complex with D48 Fab. The side view and top view were presented. The HSV-1 gB trimer and D48 Fab VH/VL were colored differently. (B) Neutralization assay ...
(A) Cryo-EM structure overview of HSV-1 gB in complex with D48 Fab. The side view and top view were presented. The HSV-1 gB trimer and D48 Fab VH/VL were colored differently. (B) Neutralization assay ...
Most notably, in vitro neutralization assays found significant increases in milk- and plasma-derived IgG neutralization efficacy, with estimated 60% and 90% improvements, respectively. Validating ...
A new study has shown that person-to-person variation in antibody immunity plays a key role in shaping which influenza (flu) strains dominate in a population. The work, published today as a Reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results